The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: A potential role of cyclooxygenase-2-dependent metabolism of 2-AG

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Valdeolivas, S ^a,b,c   Pazos, M R ^a,b,c   Bisogno, T ^d   Piscitelli, F ^d   Iannotti, F A ^d   Allara M ^d   Sagredo, O ^a,b,c   Di Marzo, V ^d   Fernandez Ruiz J ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^d CNR   (Italy)

Author keywords

Endocannabinoids; CB1 and CB2 receptors; diacyl glycerol lipase; monoacyl glycerol lipase; cyclooxygenase 2; Huntington's disease; Malonate; Neuroprotection

Indexed keywords

2 ARACHIDONOYL GLYCEROL; 4 AMINOBUTYRIC ACID; ACYLGLYCEROL LIPASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CELECOXIB; CYCLOOXYGENASE 2; ENDOCANNABINOID; GLYCEROL; MALONIC ACID; O 3841; OCTADEC 9 ENOIC ACID 1 METHOXYMETHYL 2 (FLUOROMETHYL PHOSPHINOYLOXY) ETHYL ESTER; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BRAIN SIZE; CELL CULTURE; CELL DEATH; CELL METABOLISM; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORPUS STRIATUM; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NISSL STAINING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; STRIA;

ANIMALS; ARACHIDONIC ACIDS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DEATH; CYCLOOXYGENASE 2; CYTOPROTECTION; DINOPROSTONE; ENDOCANNABINOIDS; GAMMA-AMINOBUTYRIC ACID; GLYCERIDES; INFLAMMATION MEDIATORS; L-LACTATE DEHYDROGENASE; LIPOPROTEIN LIPASE; MALE; MALONATES; MODELS, BIOLOGICAL; MONOACYLGLYCEROL LIPASES; NEOSTRIATUM; NERVE DEGENERATION; NEURONS; NITRIC OXIDE SYNTHASE TYPE II; PPAR DELTA; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84887495462     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.387     Document Type: Article

References (59)

1. Pazos MR, Sagredo O, Fernández-Ruiz J. The endocannabinoid system in Huntingtons disease. Curr Pharm Des 2008; 14: 2317-2325
2. Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S et al. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 2011; 163: 1365-1378
3. Sagredo O, Pazos MR, Valdeolivas S, Fernández-Ruiz J. Cannabinoids: Novel medicines for the treatment of Huntingtons disease. Recent Pat CNS Drug Discov 2012; 7: 41-48
4. Walker FO. Huntingtons disease. Lancet 2007; 369: 218-228
5. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: An alternative approach to Huntingtons disease. Nat Rev Neurosci 2005; 6: 919-930
6. McMurray CT. Huntingtons disease: New hope for therapeutics. Trends Neurosci 2001; 24: S32-S38
7. Wright BL, Barker RA. Established and emerging therapies for Huntingtons disease. Curr Mol Med 2007; 7: 579-587
8. Burgunder JM. Translational research in Huntingtons disease: Opening up for disease modifying treatment. Transl Neurodegener 2013; 2: 2
9. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz J, Brouillet E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport 2004; 15: 2375-2379
10. Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, Scattoni ML et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 2006; 51: 1004-1012
11. Sagredo O, Gonzá lez S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntingtons disease. Glia 2009; 57: 1154-1167
12. Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntingtons disease. J Neurosci Res 2011; 89: 1509-1518
13. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused by 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007; 26: 843-851
14. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntingtons disease excitotoxicity. Brain 2009; 132: 3152-3164
15. Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntingtons disease. Brain 2001; 134: 119-136
16. Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntingtons disease: Role of CB1 and CB2 receptors. ACS Chem Neurosci 2012; 3: 400-406
17. De Yébenes J. Phase II-clinical trial on neuroprotection with cannabinoids in Huntingtons disease (SAT-HD). EudraCT 2010-024227-24
18. Bisogno T, Di Marzo V. Short-and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacol Res 2007; 56: 428-442
19. Bisogno T, Martire A, Petrosino S, Popoli P, Di Marzo V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntingtons disease. Neurochem Int 2008; 52: 307-313
20. Lastres-Becker I, Fezza F, Cebeira M, Bisogno T, Ramos JA, Milone A et al. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntingtons disease. Neuroreport 2001; 12: 2125-2129
21. Lastres-Becker I, De Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntingtons disease. J Neurochem 2003; 84: 1097-1109
22. Toulmond S, Tang K, Bureau Y, Ashdown H, Degen S, ODonnell R et al. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntingtons disease. Br J Pharmacol 2004; 141: 689-697
23. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, Fernández-Ruiz J. Effects of cannabinoids in the rat model of Huntingtons disease generated by an intrastriatal injection of malonate. Neuroreport 2003; 14: 813-816
24. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 2003; 163: 463-468
25. Sang N, Zhang J, Chen C. COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J Neurochem 2007; 102: 1966-1977
26. Giordano M, Takashima H, Herranz A, Poltorak M, Geller HM, Marone M et al. Immortalized GABAergic cell lines derived from rat striatum using a temperature-sensitive allele of the SV40 large T antigen. Exp Neurol 1993; 124: 395-400
27. Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 2006; 1761: 205-212
28. Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol Neurobiol 2007; 36: 68-74
29. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9: 917-924
30. Brown GC. Mechanisms of inflammatory neurodegeneration: INOS and NADPH oxidase. Biochem Soc Trans 2007; 35: 1119-1121
31. Stahel PF, Smith WR, Bruchis J, Rabb CH. Peroxisome proliferator- activated receptors: key regulators of neuroinflammation after traumatic brain injury. PPAR Res 2008; 2008: 538141
32. Ortar G, Bisogno T, Ligresti A, Morera E, Nalli M, Di Marzo V. Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem 2008; 51: 6970-6979
33. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009; 5: 37-44
34. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011; 334: 809-813
35. Piro JR, Benjamin DI, Duerr JM, Pi Y, Gonzales C, Wood KM et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimers disease. Cell Rep 2012; 1: 617-623
36. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901-910
37. Tzeng SF, Hsiao HY, Mak OT. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy 2005; 4: 335-340
38. Yang H, Chen C. Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des 2008; 14: 1443-1451
39. Woodward DF, Carling RW, Cornell CL, Fliri HG, Martos JL, Pettit SN et al. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther 2008; 120: 71-80
40. Hu SS, Bradshaw HB, Chen JS, Tan B, Walker JM. Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br J Pharmacol 2008; 153: 1538-1549
41. Kozak KR, Prusakiewicz JJ, Marnett LJ. Oxidative metabolism of endocannabinoids by COX-2. Curr Pharm Des 2004; 10: 659-667
42. Kreutz S, Koch M, Böttger C, Ghadban C, Korf HW, Dehghani F. 2-Arachidonoyl-glycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. Glia 2009; 57: 286-294
43. Sun Y, Bennett A. Cannabinoids: A new group of agonists of PPARs. PPAR Res 2007; 2007: 23513
44. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527-531
45. OSullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease. Immunobiology 2010; 215: 611-616
46. Minghetti L, Greco A, Potenza RL, Pezzola A, Blum D, Bantubungi K et al. Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. J Neuropathol Exp Neurol 2007; 66: 363-371
47. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S et al. Cyclooxygenase-2 is instrumental in Parkinsons disease neurodegeneration. Proc Natl Acad Sci USA 2003; 100: 5473-5478
48. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Cyclooxygenase-1 Eikelenboom P. and -2 in the different stages of Alzheimers disease pathology. Curr Pharm Des 2008; 14: 1419-1427
49. Gopez JJ, Yue H, Vasudevan R, Malik AS, Fogelsanger LN, Lewis S et al. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery 2005; 56: 590-604
50. Wang QJ. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci 2006; 27: 317-323
51. Zhang J, Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem 2008; 283: 22601-22611
52. Du H, Chen X, Zhang J, Chen C. Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-g. Br J Pharmacol 2001; 163: 1533-1549
53. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949
54. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 1997; 322: 671-677
55. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-534
56. Gatta L, Piscitelli F, Giordano C, Boccella S, Lichtman A, Maione S et al. Discovery of prostamide F2a and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. PLoS One 2012; 7: E31111
57. Palkovits M, Brownstein J. Maps and Guide to Microdissection of the Rat Brain. Elsevier: New York-Amsterdam-London, 1988
58. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
59. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007; 14: 1347-1356